Understanding Haemonetics (HAE) Reliance on International Revenue

Haemonetics (HAE) reported a 4.4% year-over-year decline in total revenue to $321.39 million for the quarter ended June 2025, primarily due to significant misses in its key international segments including Japan, Rest of Asia, and Europe, all of which fell short of Wall Street analyst projections. This underperformance in critical overseas markets, central to the blood management systems provider's growth, has led to a sharp stock decline of 28.5% over the past four weeks and 23.2% over three months, substantially underperforming the broader S&P 500 and medical sector, and resulting in a Zacks Rank #4 (Sell) rating.

Analysis

Haemonetics (HAE) is facing significant operational headwinds, evidenced by a 4.4% year-over-year revenue decline to $321.39 million in its most recent quarter. The weakness is primarily driven by a broad-based underperformance in its international segments, which are critical to its growth profile. Revenue from Japan missed analyst consensus by a substantial 14.62%, while Europe and the Rest of Asia also fell short by 10.32% and 7.55% respectively. This indicates a systemic issue rather than a localized disruption. The forward outlook remains negative, with Wall Street analysts forecasting a further 7.1% YoY revenue decline for the current quarter and a 4.2% drop for the full fiscal year. The market has reacted severely to this news, with HAE's stock plummeting 28.5% over the past four weeks and 23.2% over the last three months, drastically underperforming both the S&P 500 and its own medical sector. This severe price depreciation, coupled with a Zacks Rank of #4 (Sell), reflects a deep-seated investor concern over the company's near-term earnings power and growth trajectory.

Key Decisions for Investors

• Given the significant revenue miss, negative forward guidance, and severe stock underperformance, investors should exercise extreme caution, and current holders may consider reducing exposure until there are clear signs of a fundamental turnaround.
• Closely monitor the performance of HAE's international segments in subsequent quarters, as a recovery in these key markets is a prerequisite for any potential positive re-rating of the stock.
• The stock's sharp downtrend and dramatic underperformance suggest a strong negative sentiment, and therefore, attempting to time a bottom is high-risk; traders should await technical confirmation of stabilization before considering a long position.